Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 32789513.
- Also identified by DOI 10.1001/jamanetworkopen.2020.17708 and PMC identifier 7426743.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This case-control study examines the association between receipt of the bradykinin 2 (B2) receptor antagonist icatibant and improved oxygenation in patients with coronavirus disease 2019 (COVID-19).
Medical subject headings
- Bradykinin
- Bradykinin B2 Receptor Antagonists
- Coronavirus Infections
- Pneumonia, Viral
- Receptor, Bradykinin B2